Oncology Pharma Stock Market Value
| ONPH Stock | USD 0 0.00 0.00% |
| Symbol | Oncology |
Oncology Pharma 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Oncology Pharma's pink sheet what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Oncology Pharma.
| 12/11/2025 |
| 01/10/2026 |
If you would invest 0.00 in Oncology Pharma on December 11, 2025 and sell it all today you would earn a total of 0.00 from holding Oncology Pharma or generate 0.0% return on investment in Oncology Pharma over 30 days. Oncology Pharma is related to or competes with Ampio Pharm. Oncology Pharma Inc., an oncology company, develops, manufactures, and commercializes therapeutics More
Oncology Pharma Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Oncology Pharma's pink sheet current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Oncology Pharma upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 58.88 | |||
| Information Ratio | 0.2033 | |||
| Maximum Drawdown | 1995.0 | |||
| Value At Risk | (66.67) | |||
| Potential Upside | 200.0 |
Oncology Pharma Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Oncology Pharma's investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Oncology Pharma's standard deviation. In reality, there are many statistical measures that can use Oncology Pharma historical prices to predict the future Oncology Pharma's volatility.| Risk Adjusted Performance | 0.1614 | |||
| Jensen Alpha | 67.25 | |||
| Total Risk Alpha | 29.95 | |||
| Sortino Ratio | 1.15 | |||
| Treynor Ratio | 19.3 |
Oncology Pharma Backtested Returns
Oncology Pharma is out of control given 3 months investment horizon. Oncology Pharma maintains Sharpe Ratio (i.e., Efficiency) of 0.23, which implies the firm had a 0.23 % return per unit of risk over the last 3 months. We were able to interpolate data for twenty-four different technical indicators, which can help you to evaluate if expected returns of 42.56% are justified by taking the suggested risk. Use Oncology Pharma Semi Deviation of 29.11, coefficient of variation of 491.2, and Risk Adjusted Performance of 0.1614 to evaluate company specific risk that cannot be diversified away. Oncology Pharma holds a performance score of 18 on a scale of zero to a hundred. The company holds a Beta of 3.5, which implies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Oncology Pharma will likely underperform. Use Oncology Pharma jensen alpha, as well as the relationship between the value at risk and skewness , to analyze future returns on Oncology Pharma.
Auto-correlation | 0.00 |
No correlation between past and present
Oncology Pharma has no correlation between past and present. Overlapping area represents the amount of predictability between Oncology Pharma time series from 11th of December 2025 to 26th of December 2025 and 26th of December 2025 to 10th of January 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Oncology Pharma price movement. The serial correlation of 0.0 indicates that just 0.0% of current Oncology Pharma price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.0 | |
| Spearman Rank Test | 0.81 | |
| Residual Average | 0.0 | |
| Price Variance | 0.0 |
Oncology Pharma lagged returns against current returns
Autocorrelation, which is Oncology Pharma pink sheet's lagged correlation, explains the relationship between observations of its time series of returns over different periods of time. The observations are said to be independent if autocorrelation is zero. Autocorrelation is calculated as a function of mean and variance and can have practical application in predicting Oncology Pharma's pink sheet expected returns. We can calculate the autocorrelation of Oncology Pharma returns to help us make a trade decision. For example, suppose you find that Oncology Pharma has exhibited high autocorrelation historically, and you observe that the pink sheet is moving up for the past few days. In that case, you can expect the price movement to match the lagging time series.
Current and Lagged Values |
| Timeline |
Oncology Pharma regressed lagged prices vs. current prices
Serial correlation can be approximated by using the Durbin-Watson (DW) test. The correlation can be either positive or negative. If Oncology Pharma pink sheet is displaying a positive serial correlation, investors will expect a positive pattern to continue. However, if Oncology Pharma pink sheet is observed to have a negative serial correlation, investors will generally project negative sentiment on having a locked-in long position in Oncology Pharma pink sheet over time.
Current vs Lagged Prices |
| Timeline |
Oncology Pharma Lagged Returns
When evaluating Oncology Pharma's market value, investors can use the concept of autocorrelation to see how much of an impact past prices of Oncology Pharma pink sheet have on its future price. Oncology Pharma autocorrelation represents the degree of similarity between a given time horizon and a lagged version of the same horizon over the previous time interval. In other words, Oncology Pharma autocorrelation shows the relationship between Oncology Pharma pink sheet current value and its past values and can show if there is a momentum factor associated with investing in Oncology Pharma.
Regressed Prices |
| Timeline |
Currently Active Assets on Macroaxis
Other Information on Investing in Oncology Pink Sheet
Oncology Pharma financial ratios help investors to determine whether Oncology Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Oncology with respect to the benefits of owning Oncology Pharma security.